Navigation Links
K-V Pharmaceutical Secures Financing Commitments Establishing Path Forward For Specialty Pharmaceutical Business
Date:11/17/2010

product development and launch, including the possibility that any product launch may be delayed;

(10)   the availability of raw materials and/or products manufactured for the Registrant under contract manufacturing agreements with third parties;

(11)   the regulatory environment, including regulatory agency and judicial actions and changes in applicable laws or regulations;

(12)   fluctuations in revenues;

(13)   the difficulty of predicting the pattern of inventory movements by the Registrant's customers;

(14)   the impact of competitive response to the Registrant's sales, marketing and strategic efforts, including introduction or potential introduction of generic or competing products against products sold by the Registrant and its subsidiaries and including competitive pricing changes;

(15)   risks that the Registrant may not ultimately prevail in litigation, including product liability lawsuits and challenges to its intellectual property rights by actual or potential competitors or to its ability to market generic products due to brand company patents and challenges to other companies' introduction or potential introduction of generic or competing products by third parties against products sold by the Registrant or its subsidiaries including without limitation the litigation and claims referred to in Note 18 – "Commitments and Contingencies" of the Notes to the Consolidated Financial Statements in the Form 10-Q, and that any adverse judgments or settlements of such litigation, including product liability lawsuits, may be material to the Registrant;

(16)   the possibility that our current estimates of the financial effect of certain announced product recalls could prove to be incorrect;

(17)   whether any product recalls or product introductions result in litigation, agency action or material damages;

(18)   failure to supply claims by certain of the
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  In a sweeping analysis assessing the current ... Exchange researchers conclude that there remains considerable room ... all age groups, but especially for adolescents and young ... diabetes treatment, underscoring the need to address barriers to ... help type 1 patients achieve optimal metabolic control. ...
(Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 ... has announced the addition of the "North ... & Graft), by Application (Surgical Wound, & Ulcer), ... Forecast to 2019" report to their offering. ... wound care market is estimated to grow at ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... Inc. and the GSK Clinical Imaging Centre (part of the GlaxoSmithKline Group ... antibody asset currently under development by GSK in the field of oncology. ... "ImaginAb is pleased to ... Behrenbruch , CEO of ImaginAb. "Not only does GSK have an excellent ...
... , SOUTH SAN FRANCISCO, Calif. , May ... from 32 prospective studies was published in The ... data shows that elevated levels of lipoprotein-associated phospholipase A2 ... increased risk of coronary heart disease similar in magnitude ...
Cached Medicine Technology:ImaginAb, Inc. and GlaxoSmithKline Establish Collaboration 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
(Date:5/22/2015)... Halifax, NS (PRWEB) May 22, 2015 ... into a sale agreement with US-based health brand Nature’s ... Ascenta Skin brand. Retention of Ascenta Skin is an ... St-Onge is excited about this opportunity to further develop ... industry. , Ascenta Skin is a breakthrough, anti-aging ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... targeted therapies can reduce tumors rapidly. However, not all ... do often develop resistance over time. Looking for a ... Fox Chase Cancer Center hypothesized that hitting already weakened ... thembut only if it was the right second agent. ...
... be improved with training and the improvement is marked ... University study. A research team led by ... of the brain that controls impulsive behavior and the ... findings could have a significant impact on the diagnosis ...
... By Steven Reinberg HealthDay Reporter , ... finds it,s safe to take the blood thinner Plavix ... that said the combination compromised Plavix,s effectiveness. "We ... and proton-pump inhibitors," said lead researcher Dr. Mette Charlot ...
... tenth anniversary of the Jackson Heart Study (JHS) will ... JHS is the largest study in history to investigate ... lung disease, stroke, diabetes, and other important diseases in ... among African-Americans than among whites in the United States. ...
... CHAPEL HILL, N.C. Scientists from University of North Carolina ... Inc. announced today findings from a large clinical study ... the worsening of osteoarthritis. The study, which was ... with X-ray evidence of knee osteoarthritis who inherited a ...
Cached Medicine News:Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 3Health News:Queen's University researchers locate impulse control center in brain 2Health News:Plavix, Heartburn Drug Safe to Take Together: Study 2Health News:NIH celebrates 10 years of research into health disparities 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 3
... respiration and ventilation., ,The Capnomac Ultima is ... monitors available. The Capnomac Ultima is available in ... measure the essential airway gas parameters, CO 2 ... O easily and reliability. The Capnomac Ultima also ...
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds as well as for gastric suctioning....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: